- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 239/95 - QuinazolinesHydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
Patent holdings for IPC class C07D 239/95
Total number of patents in this class: 312
10-year publication summary
|
21
|
12
|
14
|
20
|
28
|
23
|
18
|
19
|
27
|
10
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Gilead Sciences, Inc. | 2036 |
21 |
| Araxes Pharma LLC | 91 |
13 |
| Bristol-myers Squibb Company | 4898 |
12 |
| The Regents of the University of California | 19918 |
8 |
| Janssen Sciences Ireland Unlimited Company | 398 |
8 |
| Cerepeut, Inc. | 8 |
7 |
| Novartis AG | 10849 |
6 |
| Ideaya Biosciences, Inc. | 119 |
6 |
| Institute of Organic Chemistry and Biochemistry of the AS CR, v.v.i. | 13 |
6 |
| Southern Research Institute | 210 |
5 |
| F. Hoffmann-La Roche AG | 7925 |
4 |
| Hoffmann-La Roche Inc. | 3418 |
4 |
| Merck Patent GmbH | 5831 |
4 |
| Amgen Inc. | 4074 |
4 |
| Chelsea Therapeutics, Inc. | 17 |
4 |
| University of Louisville Research Foundation, Inc. | 720 |
4 |
| AstraZeneca AB | 2909 |
3 |
| Janssen Pharmaceutica N.V. | 3392 |
3 |
| Purdue Research Foundation | 3612 |
3 |
| Aclaris Therapeutics, Inc. | 89 |
3 |
| Other owners | 184 |